Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma

Carmell, N., Rominiyi, O. orcid.org/0000-0002-9724-0224, Myers, K.N. et al. (9 more authors) (2021) Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13 (5). 944. ISSN 2072-6694

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: ERK5; MAPK7; glioblastoma; temozolomide; DNA damage; sensitisation
Dates:
  • Accepted: 22 February 2021
  • Published (online): 24 February 2021
  • Published: 1 March 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Science (Sheffield) > School of Biological Sciences (Sheffield) > Department of Biomedical Science (Sheffield)
The University of Sheffield > Faculty of Science (Sheffield) > School of Biological Sciences (Sheffield) > Department of Molecular Biology and Biotechnology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 15 Mar 2021 16:38
Last Modified: 15 Mar 2021 16:38
Status: Published
Publisher: MDPI AG
Refereed: Yes
Identification Number: https://doi.org/10.3390/cancers13050944

Share / Export

Statistics